Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical research study is to learn if positron emission tomography (PET)/computed tomography (CT) scanning can be used to detect mantle cell lymphoma in the colon. Researchers want to learn if PET/CT scanning can produce good-quality images and/or find the exact locations of lymphoma in the body.

Primary Objective is to determine if combined CT colonography and full body PET scan is technically feasible and can produce diagnostic scans as well as accurate anatomic coordination for detection of mantle cell lymphoma involvement of the colon.


Clinical Trial Description

Colonoscopy Testing:

A colonoscopy is a routine test where the doctor looks at the inner lining of the colon using a long, flexible, lighted tube that is inserted through the anus. This is the standard procedure for detecting mantle cell lymphoma in the colon.

PET/CT Scanning:

Because PET/CT scanning is less invasive than colonoscopy, researchers want to learn more about whether PET/CT scanning may be able to be used for detecting mantle cell lymphoma in the colon.

PET/CT scanning is also considered a routine test for checking the status of mantle cell lymphoma. The scan is called "full body" because the neck, chest, abdomen (stomach area), and pelvis are included.

In this study, participants will have a full-body PET/CT procedure performed like they normally would, but the difference will be that gas will be pumped into the colon before the scan. This is so the colon will be opened up (inflated) so the study doctor will be able to more easily look for any lesions. The procedure is called gas insufflation. (In standard PET/CT scanning of the colon, gas insufflation is not used.)

Study Participation:

If you agree to take part in this study, you will begin the PET/CT procedure, as usual. This means a special substance called fluorodeoxyglucose will be injected by vein, in order to make the tumor more visible in the scanned image.

About an hour later, the study doctor will prepare your colon for the PET/CT scan by performing gas insufflation. To do so, a soft plastic tube will be inserted through your anus. Carbon dioxide gas will be automatically pumped into your colon until the gas is at the correct pressure.

If the study doctor decides it is necessary (for example, if cramping occurs), you will receive a glucagon injection under the skin in order to relax the colon. Glucagon is a medication that helps to relax the colon and decrease cramping. If continued cramping occurs, the gas will be turned off which results in immediate relief. This is considered routine for the CT part of the PET/CT. Administering the gas for the CT is similar to the sensation that will be felt during the colonoscopy when the colon is also insufflated.

After the gas insufflation, the routine PET/CT scan will be performed to check the status of the disease. You will lie on your stomach for the first part of the PET/CT scan and on your back for the second part.

After the PET/CT scan, the routine colonoscopy will be performed. You will need to sign a separate consent form for the colonoscopy, and the procedure will be explained to you in detail.

Length of Study:

Your participation in this study will be over after the PET/CT scan. Researchers will compare the results of the PET/CT scan to the results of the colonoscopy.

This is an investigational study. Gas insufflation and glucagon are FDA approved for use with CT colonography (colonoscopy that uses CT scanning), which is typically used to screen for colon cancer. PET/CT scanning is FDA approved for use in checking the status of mantle cell lymphoma. Using PET/CT scanning to detect mantle cell lymphoma in the colon, however, is investigational. For this purpose, at this time PET/CT scanning is being used in research only.

Up to 43 patients will take part in this study. All will be enrolled at M. D. Anderson. ;


Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00541424
Study type Observational
Source M.D. Anderson Cancer Center
Contact
Status Withdrawn
Phase N/A
Start date September 2007
Completion date November 2008

See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1